Could melatonin tame a devastating childhood epilepsy?
NCT ID NCT07221968
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether high doses of melatonin, a natural sleep hormone, can safely reduce abnormal brain activity in children with DEE-SWAS, a rare epilepsy that causes skill loss. Only 3 children will participate, and researchers will monitor side effects and changes in brain waves during sleep. It is an early step to see if this simple treatment might help.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Melatonin
What this could lead to
If it works, this could point toward a safe, natural treatment to reduce seizures and help children with DEE-SWAS regain lost skills.
What could go wrong
This is a very small, early-phase trial with only 3 participants. High doses of melatonin may cause side effects, and it is not yet known if it will improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CSWS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.